Channel 7 News, page-28

Yuyu,

OK thanks got it.

Reducing patient treatment cost for oncology and the general medical health bill is what will trigger interest in the drug from an investor perspective. Good for NRT.

From a prognosis perspective it seems to change little other than be a supplement to improve uptake of current chemotherapy regimes.

From a patient/carer perspective it appears to afford little benefit or improved comfort during their journey, sadly.

And assuming the in-human trials are successfully completed and all approvals are given and the product is in the market we are at least 3 years out still, yes?

Cheers.